All In Biotech

Drug Trial Radar · NCT01640782

Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach

Open Label, Randomised, Multicenter Phase III Study of Adjuvant Chemotherapy in Radically Resected Adenocarcinoma of the Stomach or Gastroesophageal Junction: Comparison of a Sequential Treatment (CPT-11+5-FU/LV --> TXT+CDDP) Versus a 5-FU/LV Regimen

Last checked: Nov 19, 2026Latest source record: Jul 18, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,100

Actual

Start

Feb 2005

Primary completion

Jan 2013

Study completion Jan 2013

Sponsor

Lead sponsor
Mario Negri Institute for Pharmacological ResearchAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Aventis Pharmaceuticals; Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente; Gruppo Oncologico Italiano di Ricerca Clinica; Gruppo Oncologico del Nord-Ovest; Italian Trial in Medical Oncology; Southern Italy Cooperative Oncology Group; Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS; Oncotech
First posted
Jul 16, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open label, randomised, multicenter, superiority study for efficacy. Patients with histologically proven adenocarcinoma of the stomach or gastroesophageal junction without gross or microscopic evidence of residual disease after surgery with curative intent and fulfilling all the inclusion/exclusion criteria are eligible for this study.

Conditions

  • Adenocarcinoma of the Stomach
  • Adenocarcinoma of the Gastroesophageal Junction

Interventions

  • Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, CisplatinDrug

    * Irinotecan (CPT-11) 180 mg/m2, given as 60 min. i.v. infusion on day 1 every 2 weeks followed by * Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by * 5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 4 administrations. After 3 weeks from last infusion: * Docetaxel (TXT) 75 mg/m2, given as a 1h i.v. infusion on day 1 followed by * Cisplatin (CDDP) 75 mg/m2, given as a 1h i.v. infusion on.day 1, every 3 weeks, for 3 cycles.

  • Leucovorin, 5-FluorouracilDrug

    * Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by * 5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 9 administrations.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival will be defined as the time from date of randomisation to date of first appearance of local, regional or distant relapse, or death from any cause; patients alive without relapse will be censored at date last known to be alive.Time frame: 3 years

Locations

101 sites in 1 country. Site status is shown where the registry gives one.

  • ASL 6 - Fabriano

    Fabriano, Ancona, Italy

  • Ospedale Civile di Senigallia

    Senigallia, Ancona, Italy

  • dell'Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I

    Torrette Di Ancona, Ancona, Italy

  • Ospedale. S. Donato

    Arezzo, Arezzo, Italy

  • Presidio Ospedaliero di Ariano Irpino

    Ariano Irpino, Avellino, Italy

  • A.O. "G. Rummo"

    Benevento, Benevento, Italy

  • Ospedali "Riuniti"

    Bergamo, Bergamo, Italy

  • A.O. "Ospedale Treviglio-Caravaggio"

    Treviglio, Bergamo, Italy

  • Ospedale degli Infermi di Biella

    Biella, Biella, Italy

  • Ospedale Maggiore-Bellaria

    Bologna, Bologna, Italy

  • A.O.Policlinico "S.Orsola-Malpighi"

    Bologna, Bologna, Italy

  • Ospedale Sant'Orsola - Fatebenefratelli

    Brescia, Brescia, Italy

  • Casa di Cura Poliambulanza di Brescia

    Brescia, Brescia, Italy

  • Spedali Civili

    Brescia, Brescia, Italy

  • P.O. di Monserrato - Policlinico Universitario di Cagliari

    Monserrato, Cagliari, Italy

  • P.O. di Monserrato

    Monserrato, Cagliari, Italy

  • P.O. Vittorio Emanuele

    Catania, Catania, Italy

  • Ospedale Garibaldi in Nesima

    Catania, Catania, Italy

  • A.O. Sant'Anna

    Como, Como, Italy

  • Ospedale "Valduce"

    Como, Como, Italy

  • Ospedale Civile "Ferrari"

    Castrovillari, Cosenza, Italy

  • Presidio Ospedaliero di Lamezia Terme

    Lamezia Terme, Cosenza, Italy

  • Ospedale "San Francesco" di Paola

    Paola, Cosenza, Italy

  • A.O. "Ospedale Maggiore" di Crema

    Crema, Crema, Italy

  • Azienda Ospedaliera "Istituti Ospitalieri" di Cremona

    Cremona, Cremona, Italy

  • P.O. S. Lazzaro

    Alba, Cuneo, Italy

  • A.O. "S.Croce e Carle"

    Cuneo, Cuneo, Italy

  • Azienda Ospedaliera Universitaria "S.Anna"

    Ferrara, Ferrara, Italy

  • Ospedale Santa Maria Annunziata

    Antella, Firenze, Italy

  • Ospedale "San Giuseppe"

    Empoli, Firenze, Italy

  • A.O. Universitaria Careggi

    Florence, Firenze, Italy

  • A.O. "G.B.Morgagni-L.Pierantoni

    Forlì, Forli, Italy

  • E.O. Ospedali Galliera di Genova

    Genova, Genova, Italy

  • Istituto Nazionale per la Ricerca sul Cancro

    Genova, Genova, Italy

  • P.O. "A.Manzoni" di Lecco

    Lecco, Lecco, Italy

  • Azienda USL 6 - P.O. Livorno

    Livorno, Livorno, Italy

  • Ospedale Civile di Casalpusterlengo

    Lodi, Lodi, Italy

  • Ospedale "Campo di Marte"

    Lucca, Lucca, Italy

  • A.O. "C.Poma"

    Mantua, Mantova, Italy

  • Ospedale Civico di Carrara

    Carrara, Massa Carrara, Italy

Showing 40 of 101 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.